You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ABLE Kids II- Advanced Biofidelic Lower Extremity Kids Prosthesis II

    SBC: ORTHOCARE INNOVATIONS LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The Advanced Biofidelic Lower Extremity Kids prosthesis (ABLE Kids) project will advance the state-of-the-art of pediatric prosthesis systems by advancing the demonstrably successful Phase I device and refining it intoan ultracompact and lightweight form factor suitable for pediatric use. Through the support of the Shriner's Hospitals in Salt Lake City, U ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Computerized Orthotic Prescription System- COPS

    SBC: ORTHOCARE INNOVATIONS LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Stiffness and alignment of ankle-foot orthoses (AFOs) should be tuned optimally to maximize their function. Improperly tuned AFO may induce joint pain, reduced ambulatory function, and increased medical complications for patients with stroke. Therefore, the relative quality of AFOs fit determined by its stiffness and alignment is of paramount concern in the d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance SelG1 into Phase II/III safety and efficacy trials to support of regulatory filings for FDA approval ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Tetravalent Vaccines for Dengue Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although dengue rarely occurs in the continental United States, it is endemic in Puerto Rico, and in many popular ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent years from individuals who show remarkably broad and potent neutralizing responses. Coupled with pas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Therapeutic Vaccines for Chronic HBV

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission. Chronic hepatitis B infection is a significant global health issue directly affecting 350 million people ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Antigen Immunoassay for Diagnosis of Coccidioidomycosis

    SBC: Immuno-mycologics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Coccidioidomycosis, also known as Valley Fever, is a fungal disease caused by Coccidioides spp. that infects an estimated 150,000 people each year in the United States. Current diagnosis of coccidioidomycosis relieson detection of anti-coccidioidal antibodies in patient sera. However, the sensitivity of this serological assay is particularly low in the firs ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Identifying the drug target in dormant cancer cells

    SBC: DORMATARG, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In spite of billions of dollars spent in the War on Cancer, cancer-specific mortality has changed little as a result, and the vast majority of cures are produced surgically, not from chemotherapy. The main problem is that even with early detection; most cancers still are detected too late and have metastasized before treatment. Although new therapies have less ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy

    SBC: Charlesson, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness. This sight-threatening condition has become a public health challenge in the US. Currently, there is no FDA- approved drugfor DR. Laser photocoagulation has remained the gold standard for the treatment of DR over the past two decades. However, laser therapy is usual ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Miniature Right Heart Support Device

    SBC: Vadovations, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure (CHF) is one of the most serious medical challenges of our day. With 5 million Americans compromised by the ravages of this disabling disease, CHF is the leading cause of Medicare hospital admissions. The economic burden exceeds 40 billion annually. A comprehensive approach to this ominous healthcare threat includes prevention and earl ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government